{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-232539","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2025-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.249688+00:00","generated_at":"2026-05-17T04:27:52.292194+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Adicet Bio: 100% renal response in Phase 1 ADI-001 lupus nephritis; plans FDA meeting Q1 2026","bullets":["Seven patients (5 LN, 2 SLE) dosed; follow-up 2–9 months as of Aug 31, 2025 cut-off.","All 5 LN patients achieved renal response: 3 complete, 2 partial; all ongoing; 3 also DORIS remission.","No serious AEs, no ICANS; only Grade 1 CRS (2 patients) and 1 Grade 1 infection; outpatient potential.","All patients discontinued immunosuppressants; discontinued or tapered corticosteroids to physiological levels.","Plans to request FDA meeting in Q1 2026 for pivotal Phase 2 trial design; enrollment continues until study opens."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-232539","json":"https://secwatch.observer/filing/0001193125-25-232539.json","markdown":"https://secwatch.observer/filing/0001193125-25-232539.md","text":"https://secwatch.observer/filing/0001193125-25-232539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525232539/0001193125-25-232539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525232539/acet-20251007.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:27:52.292194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}